According to Heartflow, its AI offering saves health systems nearly $1,400 per patient thanks to reductions in unnecessary cardiovascular testing.

“Going public is not a finish line. It’s the beginning of our next chapter,” CEO Caitlin Zulla, MPH, said in prepared remarks Dec. 11. 

A U.S. state is enjoying $50 million in annual savings after imposing price caps on its hospitals. OK—but what good things (or workers) got sacrificed?

The Barostim device from CVRx continues to gain momentum as a go-to heart failure treatment. A free webinar is scheduled to examine the device's new CPT codes, which go into effect in 2026.

The Raleigh, North Carolina-based company—which formerly went by US Radiology Specialists—is offering 25 million shares of common stock at $18.50 apiece. 

Researchers from University of Minnesota found that more than 300 small, rural hospitals didn't even apply for relief. At the same time, many larger, for-profit systems received hundreds of thousands in overpayments. The findings are published in Health Affairs.

That number includes signups on both state and federal exchanges. To date, roughly 400,000 new plans have been sold on exchanges, year over year. But the still-unknown details will determine what exactly it all means.

The American public’s trust in healthcare institutions, long a matter of common courtesy, fell off a cliff after the COVID-19 crisis. Two academic physicians propose a treatment pathway for the injured patient—aka our healthcare system’s reputation for reliability.